Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine, Inc. (IRON) – CEO Form 4 filing dated 07/08/2025
Chief Executive Officer John D. Quisel disclosed an exercise-and-sell transaction executed on 07/03/2025 under a Rule 10b5-1 trading plan adopted on 02/13/2025.
- Option exercise (Code M): 5,200 options exercised at $9.86, converting into 5,200 common shares.
- Open-market sale (Code S): the same 5,200 shares sold at a $55.0874 weighted-average price (range $55.00–$55.26), generating ≈ $0.29 million gross proceeds.
- Post-transaction ownership: 161,828 common shares held directly and 150,175 options remaining.
- The underlying option grant (09/13/2031 expiration) vests in 48 equal monthly tranches that began on 09/01/2021.
The filing represents a relatively small (< 4%) reduction in Quisel’s equity stake and appears routine, given the pre-arranged 10b5-1 plan. No company fundamentals were released.
Disc Medicine, Inc. (NASDAQ: IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi filed a Form 4 reporting the sale of 2,000 shares of common stock on 16 June 2025. The shares were sold under a previously adopted Rule 10b5-1 trading plan dated 10 March 2025 at a weighted-average price of $52.2594 per share, with individual trades executed between $51.79 and $52.61. Following the sale, Franchi’s direct beneficial ownership stands at 67,530 common shares.
No derivative securities were reported in this filing, and there were no acquisitions of additional shares or option exercises. The filing confirms that the transaction was executed directly (ownership code “D”).
The disposal represents roughly 3% of the reporting person’s post-transaction holdings and does not materially affect the company’s share count. While investors track Form 4 filings to assess insider sentiment, the modest size and pre-planned nature of this sale limit its informational weight.